Dyve Biosciences
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2545 W Hillcrest Dr Ste 215, Thousand Oa...Phone Number
(805) 857-6449Website
www.dyvebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Dyve Biosciences
Dyve Biosciences utilizes its innovative DMAX transdermal platform to provide targeted pH modulation for the treatment of various immunologic and oncologic diseases. Their lead products, DYV800 and DYV700, aim to neutralize acidic microenvironments that contribute to disease progression, enhancing therapeutic outcomes. The company focuses on delivering pH-modulating agents that are unsuitable for traditional oral or injectable delivery, thereby improving patient care. Dyve's team comprises experienced scientists and clinicians dedicated to advancing treatment standards in oncology and immunology.Explore more
Dyve Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dyve Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Dyve Biosciences launches new products
Check out if Dyve Biosciences is spiking on competitors!
Click to see if Dyve Biosciences had a recent Job posting/layoffs
Check if Dyve Biosciences has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Dyve Biosciences
Earning: See what the market has to say on Dyve Biosciences recently announced quarterly report
Dyve Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Dyve Biosciences has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Dyve Biosciences
Compare insights from companies similar to Dyve Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Dyve Biosciences
<$5M
11-50
Private
<$5M
2016
SB
Scott BarlowExecutive Vice President & General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Dyve Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Dyve Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Dyve Biosciences.
Dyve Biosciences financials insights
Gather financial insights about Dyve Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Dyve Biosciences Tech Stack
A closer look at the technologies used by Dyve Biosciences
Most Recent Scoops
Left Company
Executive Move
Executive Move
Board of Directors
Funding
Dyve Biosciences has received an SBA PPP loan for $150,000-350,000 from JPMorgan Chase Bank, supporting the retention of 11 jobs.
Funding
Dyve Biosciences News & Media
Dyve Announces Poster Presentation at 2023 AACR Annual Meeting
CAMARILLO, Calif.--(BUSINESS WIRE)-- #biotechnology--Dyve announces poster presentation at 2023 AACR annual meeting.Dyve Biosciences Appoints Tatyana Beldock to Board of Directors
CAMARILLO, Calif.--(BUSINESS WIRE)-- #biotechnology--Dyve Biosciences, a clinical-stage platform biotech with assets in immunology and oncology, announces Tatyana Beldock joins Dyve's Board of Directors.Dyve Biosciences to Participate in the BIO International Convention
CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that Chuck Harbert, Ph.D., Chief Scientific Officer of Dyve and additional members of management will be attending the Biotechnology Innovation Organization (BIO) Annual Convention taking place at the San Diego Convention Center, Monday June 13 - Thursday, June 16, 20Dyve Biosciences to Present at the 34th Annual Roth Conference
CAMARILLO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that Ryan Beal, M.D., Chief Executive Officer and Co-founder, will be participating in a fireside chat at the 34th Annual Roth Conference in Dana Point, California March 13 - 15, 2022. Company management will also be participating in one-on-one meetings throughout th
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dyve Biosciences
Sign Up For FreeTo access detailed company insights
Dyve Biosciences utilizes its innovative DMAX transdermal platform to provide targeted pH modulation for the treatment of various immunologic and oncologic diseases. Their lead products, DYV800 and DYV700, aim to neutralize acidic microenvironments that contribute to disease progression, enhancing therapeutic outcomes. The company focuses on delive... Read More
